VGX 3200

Drug Profile

VGX 3200

Alternative Names: GHRH 1-44; GHRH-1-44-NH2; Growth Hormone-Releasing Factor 44; hpGRF 44; VGX-3200

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baylor College of Medicine
  • Developer Inovio Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Anaemia; Cachexia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Anaemia in USA (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cachexia in USA (IM, Injection)
  • 30 Apr 2012 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top